| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.17 | 4e-07 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.62 | 0.0001 |
| mRNA | HLI 373 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.005 |
| mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.006 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | indisulam | CTRPv2 | pan-cancer | AAC | 0.087 | 0.007 |